Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge

Bharat K R Chaganty, Ashlesh K. Murthy, Shankar J. Evani, Weidang Li, M. Neal Guentzel, James P. Chambers, Guangming Zhong, Bernard P. Arulanandam

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We have shown previously that vaccination with recombinant chlamydial protease-like activity factor (rCPAF) plus interleukin-12 as an adjuvant induces robust protective immunity against primary genital Chlamydia muridarum challenge in mice. Since CPAF is a protease, we compared the effects of enzymatically active and inactive (heat denatured) rCPAF to determine whether proteolytic activity is expendable for the induction of protective immunity against chlamydial challenge. Active, but not inactive, rCPAF immunization induced high levels of anti-active CPAF antibody, whereas both induced robust splenic CPAF-specific IFN-γ production. Vaccination with active or inactive rCPAF induced enhanced vaginal chlamydial clearance as early as day 6 with complete resolution of infection by day 18, compared to day 30 in mock-vaccinated and challenged animals. Importantly, significant and comparable reductions in oviduct pathology were observed in active and inactive rCPAF-vaccinated mice compared to mock-vaccinated animals. Thus, rCPAF induced anti-chlamydial immunity is largely independent of enzymatic activity and secondary or higher order protein conformation.

Original languageEnglish (US)
Pages (from-to)2323-2329
Number of pages7
JournalVaccine
Volume28
Issue number11
DOIs
StatePublished - Mar 8 2010

Fingerprint

genitalia
Immunity
Peptide Hydrolases
proteinases
Hot Temperature
immunity
heat
Chlamydia muridarum
Vaccination
vaccination
protein conformation
Protein Conformation
Oviducts
interleukin-12
mice
Interleukin-12
oviducts
adjuvants
Immunization
animals

Keywords

  • Chlamydia trachomatis
  • Reproductive sequelae
  • Vaccines

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Chaganty, B. K. R., Murthy, A. K., Evani, S. J., Li, W., Guentzel, M. N., Chambers, J. P., ... Arulanandam, B. P. (2010). Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine, 28(11), 2323-2329. https://doi.org/10.1016/j.vaccine.2009.12.064

Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. / Chaganty, Bharat K R; Murthy, Ashlesh K.; Evani, Shankar J.; Li, Weidang; Guentzel, M. Neal; Chambers, James P.; Zhong, Guangming; Arulanandam, Bernard P.

In: Vaccine, Vol. 28, No. 11, 08.03.2010, p. 2323-2329.

Research output: Contribution to journalArticle

Chaganty, Bharat K R ; Murthy, Ashlesh K. ; Evani, Shankar J. ; Li, Weidang ; Guentzel, M. Neal ; Chambers, James P. ; Zhong, Guangming ; Arulanandam, Bernard P. / Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. In: Vaccine. 2010 ; Vol. 28, No. 11. pp. 2323-2329.
@article{a4a5304e1db74e1f8eb11e0624249b1d,
title = "Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge",
abstract = "We have shown previously that vaccination with recombinant chlamydial protease-like activity factor (rCPAF) plus interleukin-12 as an adjuvant induces robust protective immunity against primary genital Chlamydia muridarum challenge in mice. Since CPAF is a protease, we compared the effects of enzymatically active and inactive (heat denatured) rCPAF to determine whether proteolytic activity is expendable for the induction of protective immunity against chlamydial challenge. Active, but not inactive, rCPAF immunization induced high levels of anti-active CPAF antibody, whereas both induced robust splenic CPAF-specific IFN-γ production. Vaccination with active or inactive rCPAF induced enhanced vaginal chlamydial clearance as early as day 6 with complete resolution of infection by day 18, compared to day 30 in mock-vaccinated and challenged animals. Importantly, significant and comparable reductions in oviduct pathology were observed in active and inactive rCPAF-vaccinated mice compared to mock-vaccinated animals. Thus, rCPAF induced anti-chlamydial immunity is largely independent of enzymatic activity and secondary or higher order protein conformation.",
keywords = "Chlamydia trachomatis, Reproductive sequelae, Vaccines",
author = "Chaganty, {Bharat K R} and Murthy, {Ashlesh K.} and Evani, {Shankar J.} and Weidang Li and Guentzel, {M. Neal} and Chambers, {James P.} and Guangming Zhong and Arulanandam, {Bernard P.}",
year = "2010",
month = "3",
day = "8",
doi = "10.1016/j.vaccine.2009.12.064",
language = "English (US)",
volume = "28",
pages = "2323--2329",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "11",

}

TY - JOUR

T1 - Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge

AU - Chaganty, Bharat K R

AU - Murthy, Ashlesh K.

AU - Evani, Shankar J.

AU - Li, Weidang

AU - Guentzel, M. Neal

AU - Chambers, James P.

AU - Zhong, Guangming

AU - Arulanandam, Bernard P.

PY - 2010/3/8

Y1 - 2010/3/8

N2 - We have shown previously that vaccination with recombinant chlamydial protease-like activity factor (rCPAF) plus interleukin-12 as an adjuvant induces robust protective immunity against primary genital Chlamydia muridarum challenge in mice. Since CPAF is a protease, we compared the effects of enzymatically active and inactive (heat denatured) rCPAF to determine whether proteolytic activity is expendable for the induction of protective immunity against chlamydial challenge. Active, but not inactive, rCPAF immunization induced high levels of anti-active CPAF antibody, whereas both induced robust splenic CPAF-specific IFN-γ production. Vaccination with active or inactive rCPAF induced enhanced vaginal chlamydial clearance as early as day 6 with complete resolution of infection by day 18, compared to day 30 in mock-vaccinated and challenged animals. Importantly, significant and comparable reductions in oviduct pathology were observed in active and inactive rCPAF-vaccinated mice compared to mock-vaccinated animals. Thus, rCPAF induced anti-chlamydial immunity is largely independent of enzymatic activity and secondary or higher order protein conformation.

AB - We have shown previously that vaccination with recombinant chlamydial protease-like activity factor (rCPAF) plus interleukin-12 as an adjuvant induces robust protective immunity against primary genital Chlamydia muridarum challenge in mice. Since CPAF is a protease, we compared the effects of enzymatically active and inactive (heat denatured) rCPAF to determine whether proteolytic activity is expendable for the induction of protective immunity against chlamydial challenge. Active, but not inactive, rCPAF immunization induced high levels of anti-active CPAF antibody, whereas both induced robust splenic CPAF-specific IFN-γ production. Vaccination with active or inactive rCPAF induced enhanced vaginal chlamydial clearance as early as day 6 with complete resolution of infection by day 18, compared to day 30 in mock-vaccinated and challenged animals. Importantly, significant and comparable reductions in oviduct pathology were observed in active and inactive rCPAF-vaccinated mice compared to mock-vaccinated animals. Thus, rCPAF induced anti-chlamydial immunity is largely independent of enzymatic activity and secondary or higher order protein conformation.

KW - Chlamydia trachomatis

KW - Reproductive sequelae

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=77049094406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77049094406&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.12.064

DO - 10.1016/j.vaccine.2009.12.064

M3 - Article

C2 - 20056182

AN - SCOPUS:77049094406

VL - 28

SP - 2323

EP - 2329

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 11

ER -